TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Fast Track Recovery Feeding With a Whey Protein Infused Carbohydrate Loading Drink and Early Oral Feeding Among Surgical Gynecologic Oncology Patients: A Pragmatic Opened Labelled Trial
Brief Summary: opened labelled randomised trial. Participants will be randomly divided into control \& intervention group during admission to hospital using random numbers. Participants were randomized into two groups: the carbohydrate-protein (CHO-P) group and control (CO) group. Participants were given a specific drink to their group on the evening prior to surgery and three hours before operation. The CHO-P group received 474ml (evening drink) or 237ml (3hours prior to operation drink) of a solution contain 14% whey protein, 86% carbohydrates and 0% lipids and the CO group nil-by-mouth at 12 midnight day of operation. All participants fasted for solids for 6 hours from the operation.


Options:
A: Hospital Stay (1 Month)
B: length of post-operative hospital stay (throughout hospitalization (up to 2 weeks)); length of clear fluid toleration (throughout hospitalization (up to 1 week)); length of solid food toleration (throughout hospitalization (up to 2 weeks))
C: Disease free survival (4.5 years from surgery)
D: Length of Hospitalization Post-operation (up to 12 months); The Total Cost (RMB) (12 month)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Mindfulness for Students
Brief Summary: The aim of the study is to find out, weather the students' wellbeing and functional ability can be enhanced by two different type of mindfulness interventions: 1) face-to-face group-based training, and 2) internet-based training based in mindfulness and acceptance and commitment therapy. Study results may be used to decide whether it is worth offering mindfulness training for medical faculty students, and what kind of training would be most suitable and effective in the medical education context.


Options:
A: Connor-Davidson's Resilience Scale (CDRISC; Connor and Davidson, 2003) (Up to 3 months)
B: Change from Baseline CORE-OM measure at post-intervention and 4-month follow-up. (It is measured three weeks before the intervention starts, immediately after the 8-week intervention is finished, and 4-month after the intervention is finished.)
C: level of depression (Baseline to 3 months)
D: Physician burnout (September 2010 - June 2012)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Mindfulness for Students
Brief Summary: The aim of the study is to find out, weather the students' wellbeing and functional ability can be enhanced by two different type of mindfulness interventions: 1) face-to-face group-based training, and 2) internet-based training based in mindfulness and acceptance and commitment therapy. Study results may be used to decide whether it is worth offering mindfulness training for medical faculty students, and what kind of training would be most suitable and effective in the medical education context.


Options:
A: Number of Participants With Smoking Abstinence (4 weeks post quit day (one week following the end of treatment)); Smoking Abstinence (26 weeks post quit day); Smoking Abstinence (4 weeks post quit day (one week following the end of treatment))
B: Degree of occupational stress (Change from baseline at 4 weeks (EG4) or 8 weeks (EG8 or CG)); Degree of occupational stress (Change from baseline at 4 weeks (EG4) or 8 weeks (EG8 or CG)); Degree of burnout (Change from baseline at 4 weeks (EG4) or 8 weeks (EG8 or CG)); Degree of Self-Compassion (Change from baseline at 4 weeks (EG4) or 8 weeks (EG8 or CG))
C: Change from Baseline CORE-OM measure at post-intervention and 4-month follow-up. (It is measured three weeks before the intervention starts, immediately after the 8-week intervention is finished, and 4-month after the intervention is finished.)
D: Seven-day point-prevalence abstinence (6 weeks after beginning treatment); Seven-day point-prevalence abstinence (6 months after beginning treatment)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Pentaerithrityltetranitrat (PETN) Zur Sekundärprophylaxe Der Intrauterinen Wachstumsretardierung
Brief Summary: Approximately 10% of all pregnancies experience mal perfusion of the placenta resulting in fetal growth restriction (FGR) of the fetus. FGR is the most important cause of perinatal mortality and morbidity. Impaired placental function determined by insufficient transformation of the uterine arteries and mal-perfusion of the placenta is the leading cause of FGR. So far, there is no treatment option for pregnancies complicated by FGR and the clinical management is restricted to close monitoring, assessing for the optimal time point of delivery of the fetus threatened by intrauterine death. In a pilot study a risk reduction of 38% for the development of severe FGR and FGR or death could be demonstrated by giving the organic nitrate pentaerithrityl-tetranitrate (PETN) to patients recognized at risk for FGR by impaired uterine artery Doppler at mid gestation (Schleussner, 2014). To confirm these results this prospective randomized placebo controlled double-blinded multicentre trial, was initiated.


Options:
A: compare the gestational age at delivery (d) between sildenafil- and placebo-treated groups (6 weeks after postpartum)
B: Intact neonatal survival until term age (Term age, up to 20 weeks after randomization)
C: The principal outcome is birth weight at delivery and neonatal morbidity (Crib Score) (6 weeks)
D: Number of participants who develop intrauterine/fetal growth restriction or perinatal death. (19 weeks of pregnancy - seventh day of life)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation of the Safety and Efficacy of Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment of Malaria in HIV-infected Pregnant Women
Brief Summary: Trial to evaluate the safety and efficacy of DHA-PPQ for Intermittent Preventive Treatment (IPTp) in HIV-infected pregnant women receiving cotrimoxazole prophylaxis (CTXp) and antiretroviral (ARV) drugs and using long lasting insecticide treated nets will be conducted in Mozambique and Gabon where malaria and HIV infection are moderate to highly prevalent. In addition, the possibility for a PK interaction between DHA-PPQ and ARV drugs will be assessed in a sub-sample of participants. Women will receive ARV therapy according to national guidelines and their infants will be followed until one year of age to evaluate the impact of DHA-PPQ on MTCT-HIV.


Options:
A: Maternal parasitaemia at delivery (Delivery)
B: Prevalence of Placental Malaria (Delivery); Incidence of Malaria in Pregnant Women (Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination); Incidence of Malaria in Infants (Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)); Incidence of Malaria in Infants (Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination)
C: Placental malaria parasitemia rates measured at time of delivery, stratified by HIV status
D: To test the hypothesis that co-trimoxazole prophylaxis is not inferior to SP intermittent preventive treatment in preventing placental malaria. (Pregnancy)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Involving Clinical Pharmacists in Transitional Care to Reduce Drug-related Readmissions Among the Elderly - a Randomized Controlled Trial
Brief Summary: This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients \>75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.


Options:
A: Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide) (Hospitalization to a hospital or ED visit within 30 days of discharge (checking at least all same state facilities))
B: Time from discharge to first drug-related readmission (180 days)
C: The probability of developing medication errors over a certain period of time and recommendations to avoid such errors. (2 months)
D: Hospital readmission (30 days)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: An Open-label Randomized-Controlled Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
Brief Summary: A study of aspirin use in pregnancy to prevent high blood pressure and growth restriction of the fetus


Options:
A: Delivery with preterm-preeclampsia (Before 37 weeks of gestation)
B: The proportion of eligible women that agree to participate in the study (Throughout study completion, less than 40 weeks); Adherence to aspirin if prescribed (36 weeks); The proportion of study subjects in whom it is possible to obtain first trimester trans-abdominal uterine artery Doppler examination (36 weeks); The proportion of study subjects with a completed screening test who are issued the screening result within one week of having the test performed (1 week); Attendance at study visits (36 weeks); Satisfactory collection of all endpoints and variables (36 weeks); Any specific study protocol violations (36 weeks)
C: Prevention of preeclampsia (6 months)
D: Number of Participants With Preeclampsia (within 3 months prior to delivery)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Mother-infant Signalling During Lactation Following Late Preterm and Early Term Delivery: An Investigation of Physiological, Psychological and Anthropological Factors
Brief Summary: This research will investigate different aspects of the 'signalling' between mother and infant during breastfeeding in a stressful situation following late preterm and early term delivery, when breastfeeding is often challenging. The researcher will conduct a single-blinded randomised controlled trial in Chinese mothers who deliver a late preterm infant (LPI; 34 0/7-36 6/7 weeks of gestation) and mothers who deliver a early term infant (ETI; 37 0/7-37 6/7) and plan to exclusively breast-feed.This study will investigate the role of the milk and infant gut microbiome as a potential 'signal' in this process. A relaxation intervention (meditation tape) will be used to reduce stress levels in mothers who are expressing breast-milk or breastfeeding their infant (born at 34 0/7-37 6/7 weeks completed gestation). This study will investigate whether lower levels of stress in the mother result in more successful and effective breastfeeding, leading to improved infant outcomes (better growth, longer sleep duration and reduced crying).


Options:
A: Exclusive Breastfeeding Rates in Burkina Faso (at 3 months of age); Infant Morbidity, 2 Week Diarrhoea Prevalence (at 3 months of age); Exclusive Breastfeeding Rates in Uganda (at 3 months of age); Exclusive Breastfeeding Rates in South Africa (at 3 months of age)
B: Changes in maternal stress from baseline to 8 weeks postpartum (8 weeks)
C: proportion of patients with breastfeeding completed at 6 months (6 months)
D: Change in Length-for-age Z scores (LAZ) at 3, 6, 12, 18 and 24 months age of children in intervention vs. comparison arms, compared to the baseline LAZ at 7 days of birth. (1, 3, 6, 9, 12, 15, 18, 21 and 24 months of child's age)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Investigations on the Efficacy of Ketamine in Depression in Comparison to Electroconvulsive Therapy
Brief Summary: While there are effective treatments for depression available, some patients do not see results with these options. Often, these patients are referred to electroconvulsive therapy (ECT) which has drawbacks such as adverse side effects, cost, and limited access. Recent research shows that intravenous ketamine may be an alternative option for these patients due to its rapid antidepressant effect sustained with multiple treatments.

This study will recruit 240 participants from the ECT waiting list at the five participating hospitals, and randomize them to either the ketamine or ECT treatment arm. Participants in the ketamine treatment arm will receive 0.5mg/kg ketamine intravenously (IV) over 40 minutes as described in the study schedule. Participants in the ECT treatment arm will receive ECT as described in the study schedule and as decided by their treating physician. Throughout the study, clinical, neuroimaging, molecular, and cognitive assessments will be conducted.

The aim of this study is to show that compared to ECT, ketamine treatment produces faster results, has less side effects, requires less or shorter hospitalizations, and is less expensive. The measures collected throughout the study (clinician scales, self-reports, blood samples, and neuroimaging) may help with predicting if future patients will respond to ECT or ketamine. This could lead to faster, more effective treatment for patient with depression.


Options:
A: Measurements of BOLD signal in the brain area BA25 (Day1 (at infusion))
B: Change in depression score (14 days)
C: Montgomery-Asberg Depression Rating Scale (MADRS) (Measured daily for 12 days, where the endpoint is the primary outcome)
D: Montgomery-Asberg Depression Rating Scale (3-4 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
Brief Summary: The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.


Options:
A: Change in glycated hemoglobin (HbA1c) during 6 weeks of hypo-energetic CRHP diet compared with hypo-energetic CD diet. (6 weeks)
B: Hemoglobin A1c at month 3 (3 months into treatment); Hemoglobin A1c at month 6 (6 months into treatment); Hemoglobin A1c at month 12 (12 months into treatment); Change in Body Weight at month 3 (Baseline and 3 months into treatment); Change in Body Weight at month 6 (Baseline and 6 months into treatment); Change in Body Weight at month 12 (Baseline and 12 months into treatment)
C: Change in Hemoglobin A1c (Baseline and six months)
D: Change From Baseline Hemoglobin A1c at 12 Weeks (Baseline to 12 weeks of diet)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods
Brief Summary: Insomnia is a common sleep disorder for patients with depression. This has a major impact on the quality of life for the individual.

The aim is to investigate, whether music intervention is effective in

1. improving sleep quality,
2. reducing symptoms of depression and
3. improving quality of life

Participants use a sound pillow and selected music in the The Music Star app at home as a sleep aid in 4 weeks.


Options:
A: Sleep Quality - subjective (Change of sleep quality from baseline at 4 weeks)
B: Resiliency Scale (At 6 months)
C: Duration (minutes) of Acute Nausea (Registered the two first evenings within the first 32 hours after onset of chemotherapy during 5th cycle of chemotherapy after enrolment in study)
D: Study Measures Completion (Baseline); Study Measures Completion (4 weeks); Acceptability of the study components (4 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial
Brief Summary: The study will evaluate the benefitial and harmful effects of short-term (20 weeks) compared to long-term (14 months) mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder.


Options:
A: Clinical Global Improvement Scale (0, 1, 5, 10 week)
B: Zanarini Rating Scale for Borderline Personality Disorder (Baseline (Visit 1), Week 1 (Visit 2), Week 2 (Visit 3), Week 4 (Visit 4), Week 6 (Visit 5), Week 8 (Visit 6), Week 10 (Visit 7), Week 12 (Visit 8))
C: Social Processing (Cyberball) fMRI Task: fMRI Responses (Pre-treatment (baseline) and post-treatment (up to 2 weeks)); Ecological Momentary Assessment (EMA): Duration, Intensity, and Severity of NSSI Urges and Behavior (One week before tDCS (baseline), two weeks during tDCS (during tDCS), one week post-tDCS (post-tDCS)); Self Injurious Thoughts and Behaviors Inventory Part 1 (Pre-treatment (baseline) and post-tDCS (up to 2 weeks after baseline)); Ecological Momentary Assessment (EMA): NSSI Urges and Behavior (One week before tDCS (baseline), two weeks during tDCS (during tDCS), one week post-tDCS (post-tDCS)); Self Injurious Thoughts and Behaviors Inventory Part 2 (pre-treatment (baseline) and post-treatment (up to 2 weeks)); Self Injurious Thoughts and Behaviors Inventory Part 3 (Pre-treatment (baseline) and post-tDCS (up to 2 weeks after baseline)); Self Injurious Thoughts and Behaviors Inventory Part 4 (Pre-treatment (baseline) and post-tDCS (up to 2 weeks after baseline))
D: Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview (Assessed at baseline, and at 8, 16 and 24 months post-randomization)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial
Brief Summary: The study will evaluate the benefitial and harmful effects of short-term (20 weeks) compared to long-term (14 months) mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder.


Options:
A: Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview (Assessed at baseline, and at 8, 16 and 24 months post-randomization)
B: Drop-out (1 year); Suicidality (Suicide Attempts) (1 year)
C: Change in frequency of self-harm (suicidal and non-suicidal) behaviours over time as measured by the Suicide Attempt Self-Injury Interview (SASII) (Administered pre-treatment and every three months until 24 months)
D: Repetition of self-harm (Three months); Change scores on the Suicide Behaviors Questionnaire from baseline (Baseline and three months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial
Brief Summary: The study will evaluate the benefitial and harmful effects of short-term (20 weeks) compared to long-term (14 months) mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder.


Options:
A: Drop-out (1 year); Suicidality (Suicide Attempts) (1 year)
B: State-Trait Anxiety Inventory (week 0 (baseline)); Hamilton Anxiety Rating Scale (week 0 (baseline)); Clinical Global Impression - Severity scale (week 0 (baseline)); Clinical Global Impression - Improvement scale (week 0 (baseline)); Mini-International Neuropsychiatric Interview 5 (week 0 (screening)); Becks Depression Inventory II (week 0 (screening)); State-Trait Anxiety Inventory (week 12 (end of treatment)); Hamilton Anxiety Rating Scale (week 12 (end of treatment)); Clinical Global Impression - Severity scale (week 12 (end of treatment)); Clinical Global Impression - Improvement scale (week 12 (end of treatment)); Mini-International Neuropsychiatric Interview 5 (week 12 (end of treatment)); Becks Depression Inventory II (week 12 (end of treatment)); State-Trait Anxiety Inventory (week 24 (follow-up)); Hamilton Anxiety Rating Scale (week 24 (follow-up)); Clinical Global Impression - Severity scale (week 24 (follow-up)); Clinical Global Impression - Improvement scale (week 24 (follow-up)); Mini-International Neuropsychiatric Interview 5 (week 24 (follow-up)); Becks Depression Inventory II (week 24 (follow-up))
C: episodes of parasuicide, alcohol intoxication, institutional care (12 months)
D: Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview (Assessed at baseline, and at 8, 16 and 24 months post-randomization)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Short-term Versus Long-term Mentalization-based Therapy for Outpatients With Subthreshold or Diagnosed Borderline Personality Disorder: a Randomized Clinical Trial
Brief Summary: The study will evaluate the benefitial and harmful effects of short-term (20 weeks) compared to long-term (14 months) mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder.


Options:
A: Change in severity of borderline personality disorder assessed with the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) interview (Assessed at baseline, and at 8, 16 and 24 months post-randomization)
B: drinking - measured using the TLFB (12 weeks); craving - measured using the OCDS (12 weeks); aggression - measured using the STAE (12 weeks)
C: The primary outcome will be the composite outcome of the number of in-patient psychiatric hospitalisations, the number of A& E contacts, and the number of suicidal acts. (At both 12 and 24 months post randomisation.)
D: change from baseline in borderline symptoms after a 10 week intervention (10 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Improvement of Biochemical Markers After Reduction of Artificially Sweetened Beverages Consumption. A Clinical Randomised Trial
Brief Summary: The consumption of artificially sweetened beverages increases glucose and insulin concentrations in blood, body weight and waist circumference. However, the effect of restricting the consumption of these beverages on metabolism is unknown. Our objective is to evaluate the effect of reducing artificially sweetened beverages consumption on the metabolism of overweight and obese young adults. A randomized, blind, controlled 12 week clinical trial will be performed on overweight and obese young adults. Young adults, consumers of artificially sweetened beverages, will be randomly assign to either Control group (no changes in their alimentary habits) or Intervention group (no intake of artificially sweetened beverages). The percentage change between 0 and 12 weeks of anthropometric variables, fasting plasma concentrations of glucose, triglycerides, insulin and cholesterol will be calculated and compared.


Options:
A: Changes in metabolic syndrome parameters including insulin/glucose homeostasis and lipid/lipoprotein metabolism in sugar-sweetened beverages (SSB) consumers following regular, diet or stevia-sweetened beverages intakes for 10 weeks. (18-24 months)
B: Incident Cancer (12/31/2030); All cause and disease specific mortality (12/31/2030); Chronic diseases (12/31/2030)
C: Feasibility measured by recruitment and retention rates (1 year in a 9 year study)
D: Glucose in mg/dl (12 weeks); Triglycerides in mg/dl (12 weeks); Insulin (12 weeks); Cholesterol in mg/dl (12 weeks)

Answer: D